Wed, April 20, 2022
Tue, April 19, 2022
Mon, April 18, 2022
Sun, April 17, 2022
Thu, April 14, 2022
Wed, April 13, 2022
Tue, April 12, 2022

Mohit Bansal Upgraded (BIIB) to Buy and Increased Target to $265 on, Apr 18th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. nd-increased-target-to-265-on-apr-18th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Mohit Bansal of Wells Fargo, Upgraded "Biogen Inc." (BIIB) to Buy and Increased Target from $235 to $265 on, Apr 18th, 2022.

Mohit has made no other calls on BIIB in the last 4 months.



There are 17 other peers that have a rating on BIIB. Out of the 17 peers that are also analyzing BIIB, 10 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $219 on, Tuesday, April 12th, 2022
  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $225 on, Monday, March 28th, 2022
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $223 on, Tuesday, March 8th, 2022
  • Evan Seigerman of "BMO Capital" Downgraded from Buy to Hold and Decreased Target to $238 on, Friday, February 4th, 2022
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
  • Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
  • Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021


These are the ratings of the 7 analyists that currently disagree with Mohit


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $283 on, Tuesday, April 12th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $240 on, Friday, April 8th, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $262 on, Friday, April 8th, 2022
  • Brian Abrahams of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $248 on, Thursday, March 3rd, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Monday, February 7th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $300 on, Monday, January 24th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022

Publication Contributing Sources